JPH0463852B2 - - Google Patents

Info

Publication number
JPH0463852B2
JPH0463852B2 JP16997083A JP16997083A JPH0463852B2 JP H0463852 B2 JPH0463852 B2 JP H0463852B2 JP 16997083 A JP16997083 A JP 16997083A JP 16997083 A JP16997083 A JP 16997083A JP H0463852 B2 JPH0463852 B2 JP H0463852B2
Authority
JP
Japan
Prior art keywords
weight
clotrimazole
gel
use according
gel composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP16997083A
Other languages
Japanese (ja)
Other versions
JPS6061518A (en
Inventor
Tetsuya Yamagata
Satoru Myata
Teruhito Nakao
Akira Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Priority to JP16997083A priority Critical patent/JPS6061518A/en
Publication of JPS6061518A publication Critical patent/JPS6061518A/en
Publication of JPH0463852B2 publication Critical patent/JPH0463852B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は皮膚への親和性が高く、かつ製剤的に
安定なクロトリマゾール溶解型のゲル状外用組成
物に関するものである。 従来、皮膚真菌症の治療法としては各種抗菌剤
を軟膏、クリーム、液剤、エアゾールの形態で患
部に塗布する外用療法が繁用されているが、完全
に治療することは困難な場合が多い。 それは一般的に皮膚真菌が皮膚の最外層部を覆
つている角質層の内部に繁殖するため抗菌剤を含
有する通常の組成物の状態では浸透しにくいこと
が主因である。従つて外用療法の成果は薬剤の抗
菌力もさることながら、病変部の角質層の厚さお
よび抗菌剤の角質層内浸透力の強弱に影響される
ところが大きく、そのため抗菌製剤としては抗菌
剤が完全に溶解された均一なる製剤であり、薬剤
の安定性に優れ、強力な浸透力を有し、さらに、
皮膚への親和性を有する薬剤処方が重要なことは
言うまでもない。 ところで近年、クロトリマゾール、すなわち、
1−〔(2−クロロフエニル)ジフエニルメチル〕
イミダゾールは真菌類に対して活性で、白癬、カ
ンジダ症、癜風の治療に用いられている。 しかし、クロトリマゾールは水および有機溶剤
に極めて難溶で、溶解しうる溶媒が限られている
ため、その製剤化は制限され、現在、クリーム、
スプレー(液剤)および膣錠のみが市販されてい
る。 又、ゲル製剤に関しても特公昭57−48090にお
いて公知であるが市販には至っていない。そこで
本発明者らは、市販のクリーム、液剤および公知
のゲル製剤よりも使用方法が簡便で、使用感がよ
く、しかも皮膚への親和性が高く、更には製剤上
安定性が良いうえ治療効果を高めるクロトリマゾ
ール製剤の開発を目論み、上記の条件を十分に満
足しうる新規な処方におけるクロトリマゾールを
有効成分とする溶解型ゲル状組成物を見い出し本
発明を完成するに至つた。 本発明のゲル製剤は有効成分であるクロトリマ
ゾール、低級アルコール、グリコール類、安定化
剤、ゲル化剤、水および中和剤からなり、しかも
PH値が7〜9に調整されたゲル状組成物に関する
ものである。 つまり、本発明のゲル製剤はクロトリマゾール
0.1〜3重量%、より好ましくは0.5〜2重量%、
低級アルコールはエタノール、n−プロパノー
ル、イソプロパノール等から任意に選択したアル
コール類30〜50重量%、より好ましくは35〜45重
量%、グリコール類はプロピレングリコール、ポ
リエチレングリコール、ブチレングリコール(例
えばα−ブチレングリコール、β−ブチレングリ
コール、β,γ−ブチレングリコール、ψ−ブチ
レングリコール)等から任意に選択され、単独ま
たは併用して使用することがき、その配合量は5
〜30重量%、より好ましくは5〜20重量%、安定
化剤はジイソプロピルアジペートからなり、2〜
10重量%、より好ましくは5〜8重量%、ゲル化
剤はカルボキシビニルポリマー、ハイドロキシプ
ロピルセルロース、ハイドロキシエチレンセルロ
ースまたはメチルセルロース等が挙げられ、配合
量は0.1〜3重量%、より好ましくは0.1〜2重量
%であり、これらは単独または併用して使用する
ことができる。また中和剤としては有機アミンで
あるメタノールアミン、エタノールアミン、ジエ
タノールアミン、ジイソプロパノールアミン、ト
リエタノールアミンまたはトリイソプロパノール
アミン等が挙げられる。しかも中和剤はゲル状組
成物のPH値が7〜9の範囲、より好ましくは7.5
〜8.5の範囲に調整しうる量が必要である。また
残余の水は通常用いる水、より好ましくは精製水
が使用される。 クロトリマゾールは前記のように難溶性のため
溶解度が低く、クロトリマゾールが完全に溶解し
て澄明なゲル剤を得るためには大量の可溶性溶剤
の使用を必要とする。一方、ゲル製剤の親和性お
よび安定性を有する適当な硬さのゲル剤を得るた
めには、大量の溶剤使用は好ましくない。 本発明はこの相反する要件を、上記の各基剤を
上記の配合比率で用いることにより克服したもの
である。 かかる本発明のクロトリマゾールゲル製剤は、
低級アルコール等の揮発性溶剤が適度に含まれ、
そのうえ安定化剤でもある、皮膚親和性または浸
透促進作用、あるいは溶解作用を有するジイソプ
ロピルアジペートが配合されるため、皮膚でよく
のび、溶媒が清涼感をともない蒸散すると共に、
皮膚上にクロトリマゾールが安定、かつ濃厚な状
態で溶存する無色透明な皮膜を形成し、しかも容
易に剥離することなく、使用感も極めて良い。ま
た本例においてはクロトリマゾールが完全に溶解
しているため同薬剤が速やかに角質内に浸透し、
更に皮膚が患部を覆うため主剤であるクロトリマ
ゾールが患部に長時間接触し効力を長時間持続す
る。また、本発明のゲル剤はクロトリマゾールを
安定に維持し、分解物の生成を極端に抑制するの
で、分解物による皮膚への刺激性またはかゆみ、
あるいはその他の副作用の発生率が極めて少ない
すぐれた特徴を有するゲル製剤である。 次に、本発明のゲル製剤の製造法について説明
する。 まず最初に、クロトリマゾールを室温または
加熱下に溶解させる。にグリコール類および
水を加える、ジイソプロピルアジペートに室温
下でゲル化剤を加え撹拌する。のゲル化剤分
散液をに加え撹拌する。中和剤の水溶液を
に加え撹拌する。 尚、上記の操作方法は特に限定されるものでは
なく、室温または加熱下の状態において通常の方
法においても製造できる。また、上位の各溶剤お
よび基剤は前記の記載中より任意に選択され、配
合量においても前述の重量%内において適宜処方
される。 次に本発明のゲル製剤のPHとクロトリマゾール
の安定性との関係を確認する為にPH値がそれぞれ
異なるゲル製剤を試作し、60℃の状態で1時間保
存し、その経時変化を測定した結果を表1に示
す。尚、表1の実験結果よりPH値が酸性状態では
不安定であることが判明した。 また、本発明のゲル製剤並びに参考例(特公昭
57−48090記載の実施例1のゲル製剤)のゲル製
剤を60℃に2週間保存し、その経時変化を測定し
た結果を表2に示す。尚、表2の実験結果より本
発明のゲル製剤は安定性において大変すぐれてい
ることが判明した。 以上の実験結果からも明らかな如く、本発明の
クロトリマゾールを含有するゲル製剤は、本発明
者らにおいて最初に見い出された新規なゲル処方
であり、経時変化に対する安定性において非常に
すぐれており、抗真菌製剤として大変有用であ
る。 以下に、実施例並びに実験例を挙げて本発明を
更に具体的に説明する。 実施例 1 クロトリマゾール1gをエチルアルコール40g
に溶解しこの溶液にプロピレングリコール15gお
よび精製水23.8gを加え5分間撹拌した。一方、
ジイソプロピルアジペート8gにカルボキシビニ
ルポリマー1gを加え分散させ、この分散液を先
のクロトリマゾール溶液に加え50分間撹拌した。
これにジイソプロパノールアミン1.2gを精製水
10gに溶かした溶液を加え5分間撹拌して透明な
クロトリマゾール含有のゲル製剤を得た。PH8.2 実施例 2 クロトリマゾール1gをエチルアルコール43g
に溶解しこの溶液にプロピレングリコール10gお
よび精製水27.9gを加え5分間撹拌した。一方、
ジイソプロピルアジペート6gにカルボキシビニ
ルポリマー0.8gを加え分散させ、この分散液を
先のクロトリマゾール溶液に加え50分間撹拌し
た。これにトリエタノールアミン1.3gを精製水
10gに溶かした溶液を加え5分間撹拌して透明な
クロトリマゾール含有のゲル製剤を得た。PH8.8 実施例 3 クロトリマゾール1gをエチルアルコール35g
に溶解し、この溶液にβ−ブチレングリコール15
gおよび精製水30.5gを加え5分間撹拌した。一
方、ジイソプロピルアジペート7gにカルボキシ
ビニルポリマー0.8gを加え分散させ、この分散
液を先のクロトリマゾール溶液に加え50分間撹拌
した。これにジイソプロパノールアミン0.7gを
精製水10gに溶かした溶液を加え5分間撹拌して
透明なクロトリマゾール含有のゲル製剤を得た。
PH7.0 参考例 クロトリマゾール1gをクロタミトン4gに約
70〜80℃に加温して溶解し、これにエチルアルコ
ール40gを徐々に加えて均一な溶液となしこれに
カルボキシビニルポリマー4%水溶液20gを加え
てよく撹拌し、次に撹拌下トリエタノールアミン
10%水溶液10.8gを徐々に加え更に精製水を加え
て全量100gとなし充分撹拌した後、冷却して透
明ゲル製剤を得た。PH6.85 実験例 1 実施例1と同様にしてジイソプロパノールアミ
ンの量を適宜増減してPH6.5〜9.0の製剤を得る。
これらを60℃に保存し、1週間後の含量を測定し
たところ第1表の結果を得た。
The present invention relates to a clotrimazole-soluble gel composition that has high affinity for the skin and is pharmaceutically stable. Traditionally, topical treatments have been used to treat skin mycoses, in which various antibacterial agents are applied to the affected area in the form of ointments, creams, liquids, or aerosols, but complete treatment is often difficult. The main reason for this is that skin fungi generally grow inside the stratum corneum, which covers the outermost layer of the skin, and are therefore difficult to penetrate with normal compositions containing antibacterial agents. Therefore, the results of topical therapy are greatly influenced by the thickness of the stratum corneum at the lesion site and the penetration power of the antibacterial agent into the stratum corneum, as well as the antibacterial activity of the drug. It is a homogeneous preparation dissolved in
It goes without saying that a drug formulation that has an affinity for the skin is important. By the way, in recent years, clotrimazole, i.e.
1-[(2-chlorophenyl)diphenylmethyl]
Imidazole is active against fungi and is used to treat ringworm, candidiasis, and tinea versicolor. However, clotrimazole is extremely poorly soluble in water and organic solvents, and the number of solvents in which it can be dissolved is limited, which limits its formulation.
Only sprays (liquids) and vaginal tablets are commercially available. A gel preparation is also known in Japanese Patent Publication No. 57-48090, but it has not been commercially available. Therefore, the present inventors have developed a method that is easier to use than commercially available creams, liquids, and known gel preparations, has a good feel, has a high affinity for the skin, has good formulation stability, and has therapeutic efficacy. With the aim of developing a clotrimazole preparation that increases the effectiveness of the present invention, the present inventors have discovered a dissolving gel composition containing clotrimazole as an active ingredient in a new formulation that fully satisfies the above conditions, and have completed the present invention. The gel preparation of the present invention consists of the active ingredients clotrimazole, lower alcohols, glycols, stabilizers, gelling agents, water and neutralizing agents, and
The present invention relates to a gel composition whose pH value is adjusted to 7 to 9. In other words, the gel preparation of the present invention contains clotrimazole.
0.1 to 3% by weight, more preferably 0.5 to 2% by weight,
Lower alcohols include 30 to 50% by weight, preferably 35 to 45% by weight, of alcohols arbitrarily selected from ethanol, n-propanol, isopropanol, etc., and glycols include propylene glycol, polyethylene glycol, butylene glycol (e.g. α-butylene glycol). , β-butylene glycol, β, γ-butylene glycol, ψ-butylene glycol), etc., and can be used alone or in combination, and the blending amount is 5.
~30% by weight, more preferably 5-20% by weight, the stabilizer consisting of diisopropyl adipate, 2-30% by weight;
10% by weight, more preferably 5 to 8% by weight, gelling agents include carboxyvinyl polymer, hydroxypropyl cellulose, hydroxyethylene cellulose, methylcellulose, etc., and the blending amount is 0.1 to 3% by weight, more preferably 0.1 to 2% by weight. % by weight, and these can be used alone or in combination. Examples of the neutralizing agent include organic amines such as methanolamine, ethanolamine, diethanolamine, diisopropanolamine, triethanolamine, and triisopropanolamine. Moreover, the neutralizing agent has a pH value of the gel composition in the range of 7 to 9, more preferably 7.5.
An amount that can be adjusted within the range of ~8.5 is required. The remaining water is commonly used water, more preferably purified water. As described above, clotrimazole is poorly soluble and has low solubility, and in order to completely dissolve clotrimazole and obtain a clear gel, it is necessary to use a large amount of soluble solvent. On the other hand, in order to obtain a gel of appropriate hardness that has affinity and stability for gel formulations, it is not preferable to use a large amount of solvent. The present invention overcomes these contradictory requirements by using the above-mentioned bases in the above-mentioned mixing ratios. Such clotrimazole gel formulation of the present invention is
Contains a moderate amount of volatile solvents such as lower alcohols,
In addition, it contains diisopropyl adipate, which is also a stabilizer and has skin affinity, penetration promoting effect, or dissolving effect, so it spreads easily on the skin, and the solvent evaporates with a refreshing feeling.
Clotrimazole forms a stable and concentrated colorless transparent film on the skin, does not peel off easily, and has an extremely good feeling of use. In addition, in this example, clotrimazole is completely dissolved, so the drug quickly penetrates into the stratum corneum.
Furthermore, since the skin covers the affected area, the main ingredient, clotrimazole, comes into contact with the affected area for a long time, and its efficacy lasts for a long time. In addition, the gel of the present invention maintains clotrimazole stably and extremely suppresses the production of decomposition products, so it does not cause skin irritation or itching caused by decomposition products.
Alternatively, it is a gel preparation with excellent characteristics that causes extremely low incidence of other side effects. Next, a method for producing the gel preparation of the present invention will be explained. First, clotrimazole is dissolved at room temperature or under heat. Add glycols and water to diisopropyladipate, add gelling agent to diisopropyl adipate at room temperature, and stir. Add the gelling agent dispersion and stir. Add the aqueous solution of neutralizer and stir. Note that the above-mentioned operating method is not particularly limited, and production can also be carried out by a normal method at room temperature or under heating. Further, each of the upper solvents and bases are arbitrarily selected from the above description, and the blending amount is appropriately formulated within the above-mentioned weight percentage. Next, in order to confirm the relationship between the PH of the gel formulation of the present invention and the stability of clotrimazole, we produced trial gel formulations with different PH values, stored them at 60°C for 1 hour, and measured their changes over time. The results are shown in Table 1. The experimental results shown in Table 1 revealed that the PH value was unstable in acidic conditions. In addition, the gel preparation of the present invention and reference examples (Tokuko Sho
The gel formulation of Example 1 described in No. 57-48090 was stored at 60°C for two weeks, and its change over time was measured. Table 2 shows the results. The experimental results shown in Table 2 revealed that the gel formulation of the present invention had excellent stability. As is clear from the above experimental results, the clotrimazole-containing gel formulation of the present invention is a novel gel formulation first discovered by the present inventors, and has excellent stability against changes over time. It is very useful as an antifungal preparation. The present invention will be explained in more detail below by giving Examples and Experimental Examples. Example 1 1 g of clotrimazole and 40 g of ethyl alcohol
15 g of propylene glycol and 23.8 g of purified water were added to this solution and stirred for 5 minutes. on the other hand,
1 g of carboxyvinyl polymer was added to 8 g of diisopropyl adipate and dispersed, and this dispersion was added to the clotrimazole solution and stirred for 50 minutes.
Add 1.2g of diisopropanolamine to this and purified water.
10 g of the solution was added and stirred for 5 minutes to obtain a transparent clotrimazole-containing gel preparation. PH8.2 Example 2 1g of clotrimazole and 43g of ethyl alcohol
10 g of propylene glycol and 27.9 g of purified water were added to this solution and stirred for 5 minutes. on the other hand,
0.8 g of carboxyvinyl polymer was added to 6 g of diisopropyl adipate and dispersed, and this dispersion was added to the clotrimazole solution and stirred for 50 minutes. Add 1.3g of triethanolamine to this and purified water.
10 g of the solution was added and stirred for 5 minutes to obtain a transparent clotrimazole-containing gel preparation. PH8.8 Example 3 1g of clotrimazole and 35g of ethyl alcohol
β-Butylene glycol 15 is dissolved in this solution.
g and 30.5 g of purified water were added and stirred for 5 minutes. On the other hand, 0.8 g of carboxyvinyl polymer was added to 7 g of diisopropyl adipate and dispersed, and this dispersion was added to the clotrimazole solution and stirred for 50 minutes. A solution of 0.7 g of diisopropanolamine dissolved in 10 g of purified water was added to this and stirred for 5 minutes to obtain a transparent clotrimazole-containing gel preparation.
PH7.0 Reference example: 1g of clotrimazole to 4g of crotamiton
Heat to 70-80℃ to dissolve, gradually add 40g of ethyl alcohol to make a homogeneous solution, add 20g of 4% carboxyvinyl polymer aqueous solution and stir well, then add triethanolamine while stirring.
10.8 g of a 10% aqueous solution was gradually added, and then purified water was added to make a total amount of 100 g. After sufficient stirring, the mixture was cooled to obtain a transparent gel preparation. PH6.85 Experimental Example 1 In the same manner as in Example 1, the amount of diisopropanolamine was appropriately increased or decreased to obtain a formulation with a pH of 6.5 to 9.0.
When these were stored at 60°C and the content was measured after one week, the results shown in Table 1 were obtained.

【表】 実験例 2 実施例1〜3および参考例のゲル剤を60℃に保
存し、2週間後の含量を測定したところ第2表の
結果を得た。
[Table] Experimental Example 2 The gels of Examples 1 to 3 and Reference Examples were stored at 60°C, and the contents were measured after 2 weeks, and the results shown in Table 2 were obtained.

【表】【table】

Claims (1)

【特許請求の範囲】 1 低級アルコール30〜50重量%、グリコール類
5〜30重量%、安定化剤2〜10重量%、ゲル化剤
0.1〜3重量%および中和剤並びに残余が水より
なる基剤にクロトリマゾール0.1〜3重量%を含
有せしめ、PH値が7〜9に調整されたことを特徴
とするゲル状外用組成物。 2 低級アルコールがエタノール、プロパノール
よりなる群より選ばれる特許請求の範囲第1項記
載のゲル状外用組成物。 3 グリコール類がプロピレングリコール、ブチ
レングリコールまたはポリエチレングリコールよ
りなる群より選ばれる特許請求の範囲第1項記載
のゲル状外用組成物。 4 安定化剤がジイソプロピルアジペートよりな
る特許請求の範囲第1項記載のゲル状外用組成
物。 5 ゲル化剤がカルボキシビニルポリマー、ハイ
ドロキシエチレンセルロース、ハイドロキシプロ
ピルセルロースまたはメチルセルロースよりなる
群より選ばれる特許請求の範囲第1項記載のゲル
状外用組成物。 6 中和剤がメタノールアミン、エタノールアミ
ン、ジエタノールアミン、ジイソプロパノールア
ミン、トリエタノールアミンまたはトリイソプロ
パノールアミンの有機アミンよりなる群より選ば
れる特許請求の範囲第1項記載のゲル状外用組成
物。
[Claims] 1. 30-50% by weight of lower alcohol, 5-30% by weight of glycols, 2-10% by weight of stabilizer, gelling agent.
A gel-like external composition characterized by containing 0.1 to 3% by weight of clotrimazole in a base consisting of 0.1 to 3% by weight, a neutralizing agent, and the remainder water, and having a pH value adjusted to 7 to 9. . 2. The gel composition for external use according to claim 1, wherein the lower alcohol is selected from the group consisting of ethanol and propanol. 3. The gel composition for external use according to claim 1, wherein the glycol is selected from the group consisting of propylene glycol, butylene glycol, or polyethylene glycol. 4. The gel composition for external use according to claim 1, wherein the stabilizer comprises diisopropyl adipate. 5. The gel composition for external use according to claim 1, wherein the gelling agent is selected from the group consisting of carboxyvinyl polymer, hydroxyethylene cellulose, hydroxypropyl cellulose, or methyl cellulose. 6. The gel composition for external use according to claim 1, wherein the neutralizing agent is selected from the group consisting of organic amines such as methanolamine, ethanolamine, diethanolamine, diisopropanolamine, triethanolamine, or triisopropanolamine.
JP16997083A 1983-09-14 1983-09-14 Gelatinous external composition Granted JPS6061518A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16997083A JPS6061518A (en) 1983-09-14 1983-09-14 Gelatinous external composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16997083A JPS6061518A (en) 1983-09-14 1983-09-14 Gelatinous external composition

Publications (2)

Publication Number Publication Date
JPS6061518A JPS6061518A (en) 1985-04-09
JPH0463852B2 true JPH0463852B2 (en) 1992-10-13

Family

ID=15896184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16997083A Granted JPS6061518A (en) 1983-09-14 1983-09-14 Gelatinous external composition

Country Status (1)

Country Link
JP (1) JPS6061518A (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61151117A (en) * 1984-12-25 1986-07-09 Bayer Yakuhin Kk Gelatinous antimycotic preparation
JPS61252247A (en) * 1985-05-02 1986-11-10 Mitsubishi Acetate Co Ltd Transparent gel composition
JPS61252246A (en) * 1985-05-02 1986-11-10 Mitsubishi Acetate Co Ltd Transparent gel composition
JPS61257920A (en) * 1985-05-13 1986-11-15 Sato Seiyaku Kk Antimycotic gelatinous agent for external use
US5288486A (en) * 1985-10-28 1994-02-22 Calgon Corporation Alcohol-based antimicrobial compositions
US5110809A (en) * 1988-03-21 1992-05-05 Bristol-Myers Squibb Company Antifungal gel formulations
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
JPH0725675B2 (en) * 1989-05-08 1995-03-22 ホーユー株式会社 Liquid mycosis agent
DE4337945A1 (en) * 1993-11-06 1995-05-11 Labtec Gmbh Plasters for the treatment of nail mycoses
JP3081766B2 (en) * 1994-05-06 2000-08-28 東興薬品工業株式会社 Keratin storage type antifungal external composition
KR100342945B1 (en) * 1999-03-09 2002-07-02 민경윤 dermal pharmaceutical composition of antifungal agent and process for the preparation thereof
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
KR100511114B1 (en) * 2002-07-16 2005-08-31 우원홍 Composition including antifungal-agents of external application for skin-whitening and external application having the same
US9554984B2 (en) 2003-11-03 2017-01-31 Jaleva Pharmaceuticals, Llc Oral care compositions for topical application
EP1947934A4 (en) 2005-11-07 2012-04-25 Jaleva Llc Film-forming resins as a carrier for topical application of pharmacologically active agents
CA2673976C (en) * 2006-12-28 2015-02-17 Kaken Pharmaceutical Co., Ltd. Gel composition for treating mycosis
JP2011173823A (en) * 2010-02-24 2011-09-08 Hisamitsu Pharmaceut Co Inc Gel preparation

Also Published As

Publication number Publication date
JPS6061518A (en) 1985-04-09

Similar Documents

Publication Publication Date Title
JPH0463852B2 (en)
US6239177B1 (en) Tranilast-containing preparation for external application and method of producing the same
US4678666A (en) Topical anti-inflammatory compositions
JP3081766B2 (en) Keratin storage type antifungal external composition
CN101932305A (en) Transdermal pharmaceutical composition containing steroid hormone
JPS6135166B2 (en)
JPWO1997028793A1 (en) Tranilast-containing topical preparation and its manufacturing method
JP2555555B2 (en) Antifungal topical formulation
JP2001513093A (en) Topical Nimusulide gel system
JPH07223971A (en) Skin external preparation
JP2004518696A (en) Antifungal topical preparation
JPH07557B2 (en) Composition for treating dermatitis
JPS6218526B2 (en)
US5817675A (en) Compositions for the treatment of psoriasis and their use
KR20020038595A (en) Topical Formulations Comprising Skin Penetration Agents and the Use Thereof
US4602040A (en) Meclofenamic acid topical pharmaceutical composition
JPH0481569B2 (en)
JPS58172312A (en) Nifedipine topical preparation
JPH0231052B2 (en)
CA2515259C (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
EP2340016B1 (en) Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
CN116942602B (en) A kind of tofacitinib citrate pharmaceutical composition
JPH0242812B2 (en)
CA2244679C (en) Tranilast-containing preparation for external application and method of producing the same
JPH05117141A (en) Antiinflammatory analgesic gel preparation containing adrenal essence